# An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

> **NCT04820309** · PHASE3 · COMPLETED · sponsor: **Karuna Therapeutics, Inc., a Bristol Myers Squibb company** · enrollment: 566 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Xanomeline and Trospium Chloride Capsules

## Key facts

- **NCT ID:** NCT04820309
- **Lead sponsor:** Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-02
- **Primary completion:** 2024-05-24
- **Final completion:** 2024-05-24
- **Target enrollment:** 566 (ACTUAL)
- **Last updated:** 2025-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04820309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04820309, "An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04820309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*